Royal Biologics launched MAGNUS, a viable cellular bone allograft. MAGNUS employs viable spine-derived cells collected from a donor’s vertebral body that are preserved with a next-generation DMSO-free cryoprotectant.
Industry standard DMSO penetrates and dehydrates the cell from within to prevent crystal formation. At room temperature, DMSO-based cryoprotectants raise concerns about cytotoxicity and negative effects on cell differentiation.
In a recently-published peer-reviewed study of 75 consecutive cases at one-year follow-up, minimally invasive transforaminal lumbar interbody fusion with MAGNUS Viable Allograft demonstrated a 96% fusion rate of the 75 patients with a total of 85 levels achieving fusion at 12 months.
Royal Biologics launched MAGNUS, a viable cellular bone allograft. MAGNUS employs viable spine-derived cells collected from a donor's vertebral body that are preserved with a next-generation DMSO-free cryoprotectant.
Industry standard DMSO penetrates and dehydrates the cell from within to prevent crystal formation. At room temperature,...
Royal Biologics launched MAGNUS, a viable cellular bone allograft. MAGNUS employs viable spine-derived cells collected from a donor’s vertebral body that are preserved with a next-generation DMSO-free cryoprotectant.
Industry standard DMSO penetrates and dehydrates the cell from within to prevent crystal formation. At room temperature, DMSO-based cryoprotectants raise concerns about cytotoxicity and negative effects on cell differentiation.
In a recently-published peer-reviewed study of 75 consecutive cases at one-year follow-up, minimally invasive transforaminal lumbar interbody fusion with MAGNUS Viable Allograft demonstrated a 96% fusion rate of the 75 patients with a total of 85 levels achieving fusion at 12 months.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
